Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Immunology | Neurology | Infections and Infectious Diseases | Vaccines
Meningitis Clinical Trials
A listing of Meningitis medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Radiant Research - Birmingham
Meningitis Vaccine Research
View More »
Birmingham : Alabama Clinical Therapeutics 806 St. Vincent's Drive, Suite 615
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Birmingham :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Pinson :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Arizona
Chandler : Radiant Research
Meningitis Vaccine Research Study
Tucson : Radiant Research - Tucson
Meningitis Vaccine Research
View More »
Chandler : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Tucson :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Arkansas
Fayetteville :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Harrisburg : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Jonesboro :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Little Rock :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
California
Chino :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Downey : Premier Health Research 9317 Firestone Blvd.
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Downey :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
La Puente :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Lakewood :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
View More »
Oakland : Kaiser Permanente Oakland 3505 Broadway, 6th Floor, Room 624
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Paramount : Center for Clinical Trials, LLC 16415 S. Colorado Ave., Suite 308
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Paramount : Center for Clinical Trials, LLC 16660 Paramount Blvd., Suite 301
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Paramount :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Pleasanton : Kaiser Permanente Pleasanton 7601 Stoneridge Drive, Second Floor
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
San Diego : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
San Francisco : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
San Francisco : Kaiser Permanente San Francisco 2200 O'Farrell St., Sixth Floor
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Santa Clara : Kaiser Permanente Santa Clara 710 Lawrence Expressway, Pediatric Clinic Department
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Colorado
Denver : Radiant Research - Denver
Meningitis Vaccine Research Study
Connecticut
Norwich :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Florida
DeLand : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Jacksonville : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
South Miami : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Georgia
Marietta :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Woodstock :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Idaho
Meridian : Advanced Clinical Research, ID
Meningitis Vaccine Clinical Trial (10-12 year olds)
Illinois
Chicago : Children's Memorial Hospital 2300 Children's Plaza, Box 155
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Dekalb :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Indiana
Indianapolis :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Iowa
Council Bluffs : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Kansas
Wichita : Via Christi Research
Safety, Tolerance & Immunogenic Response to Vaccine for MCV4, TDaP & Bivalent rLP2086 in Children 10-12
Kentucky
Bardstown : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Bardstown : Kentucky Pediatric/Adult Research 201 South Fifth Street, Suite 102
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Louisiana
Bossier City :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Maryland
Annapolis : 28 Annapolis Pediatrics, 200 Forbes Street, Suite 200
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Massachusetts
Woburn :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Worcester :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Minnesota
Missouri
St. Louis : Radiant Research - St. Louis
A Clinical Research Study for Meningitis Vaccine (People 56+)
St. Louis : Radiant Research - St. Louis
Meningitis Research Study
View More »
Bridgeton :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Kansas City :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Nebraska
Elkhorn :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Fremont : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Lincoln :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Omaha :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
New York
Rochester : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
North Carolina
Raleigh : PMG Research of Raleigh
What is Meningococcal Disease? Is my child at risk?
View More »
Clyde :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
North Dakota
Fargo :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Ohio
Akron : Radiant Research - Akron
Meningitis Vaccine Research Study
Cleveland : Rapid Medical Research, Inc. (RMR)
Has your child received a meningitis vaccine?
Cleveland : Rapid Medical Research, Inc. (RMR)
Meningitis Vaccine Clinical Trial (10-12 year olds)
Cleveland : Rapid Medical Research, Inc. (RMR)
Meningitis Vaccine Study: What is Meningococcal Disease Type B?
View More »
Cincinnati :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Cleveland : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Cleveland : Senders Pediatrics 2054 South Green Road
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Fairfield :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Huber Heights : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Huber Heights :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Kettering :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Oklahoma
Tulsa :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Pennsylvania
Erie : Children's Health Care 2501 West 12th Street
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Erie :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Harleysville :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Harleyville : Pennridge Pediatric Associates 270 Main Street
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Hermitage : Kid's Way Pediatrics 3068 Innovation Way
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
View More »
Hermitage :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Pittsburgh : UPMC
Cerebrospinal Fluid Pharmacokinetics of Daptomycin
Scranton :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Sellersville : Pennridge Pediatric Associates 711 Lawn Avenue
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Sellersville :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Suite 300 Rydal : Pediatric Medical Associates 1077 Rydal Road
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Suite D2 East Norriton : Pediatric Medical Associates 160 West Germantown Pike
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Upper St. Clair : PEAK Research 2859 Washington Rd., Ste. 412B
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
South Carolina
Anderson : Radiant Research - Anderson
Meningitis Vaccine (Pediatric) Research Study
Anderson : Radiant Research - Anderson
What's News @ Radiant Research Anderson
Mount Pleasant : PMG Research of Charleston
What is Meningococcal Disease? Is my child at risk?
Mt. Pleasant : Coastal Carolina Research Center
Healthy volunteers (ages 10 to 25) needed for vaccine research study for prevention of meningitis
Mt. Pleasant : Coastal Carolina Research Center
Healthy volunteers (Ages 11 to 25) needed for vaccine research study for prevention of meningitis.
View More »
Mt. Pleasant : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Tennessee
Bristol : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Jackson :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Kingsport :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Texas
Dallas : Research Across America
Meningococcal Vaccine Research Study
Dallas : Radiant Research - Dallas, North
Vaccine Research for Meningitis B
Houston : DM Clinical Research
Pediatric Meningitis Vaccine- Houston,TX
San Antonio : Radiant Research - San Antonio
Meningitis Vaccine Research
View More »
Austin :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Dallas : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Dallas :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Fort Worth : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Fort Worth :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Houston : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Houston :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Hurst :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Katy : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
San Antonio : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
San Antonio :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Utah
Murray : Radiant Research - Salt Lake City
Meningitis Research Study
Murray : Radiant Research - Salt Lake City
Vaccine Research for Meningitis B
Salt Lake City : J. Lewis Research, Inc.
Meningitis B Vaccine
West Jordan : Advanced Clinical Research, UT
Has Your Child Received a Meningitis Vaccine?
West Jordan : Advanced Clinical Research, UT Updated
Meningitis Type B Vaccine
West Jordan : Advanced Clinical Research, UT
Meningitis Vaccine Clinical Trial (10-12 year olds)
View More »
Layton :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Murray :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Orem :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Payson :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Roy :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Salt Lake City : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
South Jordan : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Spanish Fork :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Syracuse :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
West Jordan : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Virginia
Burke : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Charlottesville : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Midlothian :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Washington
Spokane :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Australia
Maroubra : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Sherwood : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Subiaco : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Westmead : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Belgium
Leuven :
A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age
Brazil
Rua Borges Lagoa 770 : Site 53 - CRIE UNIFESP Updated
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
Rua Marselhesa 500 Vila Clementino : Site 50 - Associacao Fundo de Incentivo a Psicofarmacologia Updated
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
Burundi
Bujumbura : Hôpital Prince Régent Charles
Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Burundi
Bujumbura : CHU Kamenge
Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Burundi
Bururi : Hôpital général
Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Burundi
Kayanza : Hôpital général
Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Burundi
Muyinga : Hôpital général
Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Burundi
Czech Republic
Ceska Skalice : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Chlumec nad Cidlinou : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Holice : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Hradec Kralove : Fakulta vojenskeho zdravotnictvi UO
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Hradec Kralove : Biovomed
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
View More »
Hradec Králové : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Hradec Králové : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Hronov : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Hronov : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Jaromer : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Jaromer : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Jindrichuv Hradec : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Jindrichuv Hradec : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Jindrichuv Hradec : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Nachod : Nemocnice Náchod
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Pardubice : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Pardubice : Nemocnice Pardubice
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Pardubice : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Sezemice : Ordinace praktickeho lekare pro deti a dorost
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Finland
Pori : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Tampere : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
Turku : Pfizer Investigational Site
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
France
Caen : François Baclesse Center
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
Lille : Oscar Lambret Center
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
Lyon : Léon Bérard Center
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
Paris : Pitie Salpetriere Hospital
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
Paris : Institut Curie - Claudius Regaud Hospital
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
View More »
Saint-Cloud : Rene Huguenin Hospital
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis
Italy
Florence : Universita di Firenze -Pediatria
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Milan : IRCCS Cà Granda
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Novara : Ospedale Maggiore della Carita
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Padova : Dip Pediatria AO Padova
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Japan
Nagoya : Japanese Red Cross Nagoya Daiichi Hospital
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection
Nagoya : National hospital Organization Nagoya Medical Center
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection
Sapporo : Sapporo Hokuyu Hosipital
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection
Shimotsuga-gun : Dokkyo Medical University Hospital
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection
Yokohama : Kanagawa Children's Medical Center
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection
Philippines
Alaminos City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Angeles City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Angeles City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Angeles City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Angeles City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
View More »
Bacolod City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Bacolod City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Bacolod City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Bacolod City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Bacoor :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Baguio City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Baguio City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Baguio City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Baguio City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Baguio City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Baguio City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Balanga City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Baliwag :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Batangas City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Batangas City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Batangas City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Binan :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Bocaue :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Cabanatuan City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Cagayan De Oro City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Cagayan De Oro City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Calamba :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Calamba :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Calamba :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Caloocan City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Caloocan City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Cardona :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Cauayan :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Cavite City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Cebu :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Cebu :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Cebu :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Cebu :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Concepcion :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Concepcion :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Dagupan City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Dasmarinas :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Dasmarinas :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Davao City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Davao City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Fairview :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
General Santos City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
General Santos City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
General Santos City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Guagua :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Iligan City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Iloilo City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Iloilo City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Imus :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Imus :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Imus :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Kidapawan City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
La Trinidad :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Laoag City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Las Pinas :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Las Pinas City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Lipa :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Lipa City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Los Banos :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Maasin City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Makati :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Makati City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Malabon City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Malolos :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Mandaluyong :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Manila :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Marikina :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Marikina City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Marikina City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Montalban :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Muntinlupa :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Muntinlupa :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Naguila :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Navotas City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Noveleta :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Olongapo City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Olongapo City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Ormoc City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Ormoc City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Ortigas :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Paranaque :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Paranaque :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Pasay :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Pasay :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Pasig :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Pasig :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Pasig City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Plaridel :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Pulilan :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Quezon City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Quezon City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Quezon City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Quezon City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Quezon City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Quezon City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Roxas :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Roxas City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
San Fernando City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
San Fernando City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
San Fernando City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
San Jose City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
San Jose Del Monte :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
San Miguel :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
San Pedro :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Sta. Rosa :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Sta. Rosa :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Sta. Rosa :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Tacloban City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Tacloban City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Tacloban City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Tagug :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Taguig :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Taguig :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Tagum City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Talisay City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Tanauan :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Tanauan :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Tarlac City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Tarlac City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Tarlac City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Taytay :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Taytay :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Theresa :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Urdaneta City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Valenzuela City :
Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Puerto Rico
Ponce :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
San Juan :
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Spain
Santiago de Compostela A Coruña : Hospital Clinico Universitario de Santiago de Compostela
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Valencia : Hospital Universitario Dr. Peset
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Valencia : Centro Superior de Investigacion en Salud Publica/Clinica Universitaria San Vicente Martir
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Vigo Pontevedra : Complexo Hospitalario Xeral Cies
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Togo
Cinkassé : Centre médico-social (CMS)
Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013
Dapaong : Clinique Win' Pang
Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013
Dapaong : Polyclinique
Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013
Dapaong : Centre Hospitalier Régional (CHR) Savanes
Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013
Dapaong : Hôpital d'enfants Yendubé
Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013
United Kingdom
Bristol : North Bristol NHS Trust
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Exeter : Royal Devon and Exeter NHS Foundation Trust
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
London : St Georges Hospital
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
Oxford : Oxford Vaccine Group - Centre for Clinical Vaccinology and Tropical Medicine Churchill Hospital
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1